PE20000476A1 - Compuestos triciclicos sustituidos - Google Patents
Compuestos triciclicos sustituidosInfo
- Publication number
- PE20000476A1 PE20000476A1 PE1999000320A PE00032099A PE20000476A1 PE 20000476 A1 PE20000476 A1 PE 20000476A1 PE 1999000320 A PE1999000320 A PE 1999000320A PE 00032099 A PE00032099 A PE 00032099A PE 20000476 A1 PE20000476 A1 PE 20000476A1
- Authority
- PE
- Peru
- Prior art keywords
- conh2
- alkyl
- refers
- optionally substituted
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- -1 CYCLOHEXENYL Chemical class 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000019054 Group II Phospholipases A2 Human genes 0.000 abstract 1
- 108010026929 Group II Phospholipases A2 Proteins 0.000 abstract 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 abstract 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS TRICICLICOS DE FORMULA I, DONDE Z ES CICLOHEXENILO O FENILO; R20 ES 1)-ALQUILO C5-C20, -ALQUENILO C5-C20, -ALQUINILO C5-C20 OPCIONALMENTE SUSTITUIDOS; 2)-L-R80; L ES UN GRUPO DE UNION DIVALENTE SELECCIONADO DE CARBONO, OXIGENO, NITROGENO, AZUFRE; R80 ES LO DEFINIDO EN 1) PARA R20; R21 ES UN SUSTITUYENTE NO INTERFERENTE; f ES 1-3; R1 ES -NHNH2; -NH2, -CONH2; R2` ES -OH, -O(CH2)tR5'; R5' ES H, -CN, -NH2, -CONH2, -CONR9R10, -NHSO2R15, -CONHSO2R15; R15 ES -ALQUILO C1-C6, -CF3, FENILO OPCIONALMENTE SUSTITUIDO; R3' ES UN SUSTITUYENTE NO INTERFERENTE, RADICALES CARBOCICLICOS, RADICALES HETEROCICLICOS OPCIONALMENTE SUSTITUIDOS; R9 Y R10 SON H, -CF3, -ALQUILO C1-C4, FENILALQUILO C1-C4. TAMBIEN SE REFIERE A UN COMPUESTO DE FORMULA II, DONDE R1 ES -NHNH2, -NH2; R2 ES -OH, -O(CH2)mR5; R5 ES H, -CO2H, -CONH2, ENTRE OTROS. UN COMPUESTO PREFERIDO ES HIDRAZIDA DEL ACIDO 9-BENCIL-5,7-DIMETOXI-1,2,3,4-TETRAHIDROCARBAZOL-4-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN INHIBIDOR DE LA LIBERACION DE ACIDOS GRASOS MEDIADA POR LA FOSFOLIPASA A2 SECRETORA NO PANCREATICA HUMANA (sPLA2) POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE SEPSIS, CHOQUE SEPTICO, ARTRITIS REUMATOIDE, OSTEOARTRITIS, ACCIDENTES CEREBROVASCULARES, APOPTOSIS, ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6232898A | 1998-04-17 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000476A1 true PE20000476A1 (es) | 2000-06-02 |
Family
ID=22041763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000320A PE20000476A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos sustituidos |
| PE1999000314A PE20000432A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos sustituidos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000314A PE20000432A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos sustituidos |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP0952149B1 (es) |
| JP (2) | JPH11322713A (es) |
| KR (2) | KR19990083232A (es) |
| CN (1) | CN1149193C (es) |
| AR (2) | AR018186A1 (es) |
| AT (2) | ATE271037T1 (es) |
| AU (2) | AU753547B2 (es) |
| BR (2) | BR9902365A (es) |
| CA (2) | CA2269246C (es) |
| CO (2) | CO5011054A1 (es) |
| CZ (2) | CZ137099A3 (es) |
| DE (2) | DE69918590T2 (es) |
| DK (1) | DK0950657T3 (es) |
| DZ (1) | DZ2769A1 (es) |
| EA (2) | EA002816B1 (es) |
| ES (2) | ES2226286T3 (es) |
| HU (2) | HUP9901221A3 (es) |
| ID (2) | ID23761A (es) |
| IL (2) | IL129485A0 (es) |
| NO (2) | NO314400B1 (es) |
| NZ (3) | NZ507564A (es) |
| PE (2) | PE20000476A1 (es) |
| PL (2) | PL332566A1 (es) |
| PT (1) | PT950657E (es) |
| SG (2) | SG81977A1 (es) |
| SI (1) | SI0950657T1 (es) |
| TR (2) | TR199900843A2 (es) |
| TW (1) | TWI238160B (es) |
| YU (2) | YU18999A (es) |
| ZA (2) | ZA992772B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9123198A (en) * | 1997-08-28 | 1999-03-16 | Eli Lilly And Company | Method for treatment of non-rheumatoid athritis |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
| WO2000037022A2 (en) * | 1998-12-21 | 2000-06-29 | Eli Lilly And Company | Combination therapy for the treatment of sepsis |
| US6706752B1 (en) | 1999-07-19 | 2004-03-16 | Eli Lilly And Company | sPLA2 inhibitors |
| DE60032774D1 (de) * | 1999-07-19 | 2007-02-15 | Lilly Co Eli | Spla2 inhibitoren |
| WO2002000257A1 (en) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Remedies for alzheimer's disease |
| ES2294003T3 (es) * | 2000-06-29 | 2008-04-01 | Anthera Pharmaceuticals, Inc. | Remedios contra el cancer. |
| WO2002000256A1 (fr) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Remedes contre la cirrhose |
| CN1450893A (zh) * | 2000-07-14 | 2003-10-22 | 伊莱利利公司 | 治疗脓毒症的方法 |
| WO2002050034A2 (en) * | 2000-12-18 | 2002-06-27 | Eli Lilly And Company | Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| ATE353876T1 (de) * | 2001-03-28 | 2007-03-15 | Lilly Co Eli | Substituierte carbazole als inhibitoren von spla2 |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| DE10249055A1 (de) | 2002-10-22 | 2004-05-06 | Bayer Cropscience Ag | 2-Phenyl-2-substituierte-1,3-diketone |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| EP1988098A1 (en) * | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| CN101981012A (zh) | 2008-03-26 | 2011-02-23 | 第一三共株式会社 | 新的四氢异喹啉衍生物 |
| CA2721060A1 (en) | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| US8580795B2 (en) | 2009-01-22 | 2013-11-12 | Orchid Chemicals & Pharmaceuticals Limited | Heterocyclic compounds as phosphodiesterase inhibitors |
| JP2012523425A (ja) | 2009-04-07 | 2012-10-04 | インフイニトイ プハルマセウトイカルス インコーポレイテッド | 脂肪酸アミドヒドロラーゼの阻害薬 |
| JP2012523424A (ja) | 2009-04-07 | 2012-10-04 | インフイニトイ プハルマセウトイカルス インコーポレイテッド | 脂肪酸アミドヒドロラーゼの阻害薬 |
| RU2569061C2 (ru) | 2010-02-03 | 2015-11-20 | Инфинити Фармасьютикалз, Инк. | Ингибиторы амид-гидролазы жирных кислот |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| CN102816107B (zh) * | 2012-08-20 | 2015-06-03 | 东南大学 | 咔唑衍生物及其制备方法与用途 |
| MX2015006871A (es) | 2012-11-30 | 2015-09-16 | Ge Healthcare Ltd | Proceso de cristalizacion de derivados de indoles triciclicos. |
| WO2014083163A1 (en) * | 2012-11-30 | 2014-06-05 | Ge Healthcare Limited | Zinc halide mediated cyclization process leading to tricyclic indoles |
| WO2016116527A1 (de) * | 2015-01-20 | 2016-07-28 | Cynora Gmbh | Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen |
| CN108707104A (zh) * | 2018-08-07 | 2018-10-26 | 北京恒信卓元科技有限公司 | 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579534A (en) * | 1969-05-09 | 1971-05-18 | American Cyanamid Co | Tetrahydrocarbazolecarboxylates |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| CA2110514A1 (en) * | 1991-07-05 | 1993-01-21 | Raymond Baker | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| ES2151993T3 (es) * | 1995-06-23 | 2001-01-16 | Lilly Co Eli | 1,2,3,4-tetrahidro-9h-carbazoles 6-sustituidos y 10h-ciclohepta(7,6-b)indoles 7-sustituidos. |
| AU1289797A (en) * | 1995-12-13 | 1997-07-03 | Eli Lilly And Company | Naphthyl acetamides as spla2 inhibitors |
| AU734096B2 (en) * | 1996-10-30 | 2001-06-07 | Eli Lilly And Company | Substituted tricyclics |
| JP2001517707A (ja) * | 1997-09-26 | 2001-10-09 | イーライ・リリー・アンド・カンパニー | 嚢胞性繊維症の処置方法 |
| EP1043991A4 (en) * | 1997-11-14 | 2005-02-02 | Lilly Co Eli | TREATMENT OF ALZHEIMER DISEASE |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
-
1999
- 1999-04-14 DZ DZ990069A patent/DZ2769A1/xx active
- 1999-04-15 IL IL12948599A patent/IL129485A0/xx unknown
- 1999-04-15 ID IDP990341D patent/ID23761A/id unknown
- 1999-04-15 IL IL12948399A patent/IL129483A0/xx unknown
- 1999-04-15 ID IDP990340D patent/ID23287A/id unknown
- 1999-04-16 KR KR1019990013436A patent/KR19990083232A/ko not_active Withdrawn
- 1999-04-16 AT AT99302967T patent/ATE271037T1/de active
- 1999-04-16 AU AU23819/99A patent/AU753547B2/en not_active Ceased
- 1999-04-16 AR ARP990101770A patent/AR018186A1/es not_active Application Discontinuation
- 1999-04-16 TR TR1999/00843A patent/TR199900843A2/xx unknown
- 1999-04-16 ES ES99302967T patent/ES2226286T3/es not_active Expired - Lifetime
- 1999-04-16 HU HU9901221A patent/HUP9901221A3/hu unknown
- 1999-04-16 BR BR9902365-2A patent/BR9902365A/pt not_active IP Right Cessation
- 1999-04-16 AR ARP990101771A patent/AR018593A1/es active IP Right Grant
- 1999-04-16 CN CNB991079574A patent/CN1149193C/zh not_active Expired - Fee Related
- 1999-04-16 CO CO99022897A patent/CO5011054A1/es unknown
- 1999-04-16 SG SG9901869A patent/SG81977A1/en unknown
- 1999-04-16 CO CO99022884A patent/CO5031247A1/es unknown
- 1999-04-16 EA EA199900303A patent/EA002816B1/ru not_active IP Right Cessation
- 1999-04-16 YU YU18999A patent/YU18999A/sh unknown
- 1999-04-16 PE PE1999000320A patent/PE20000476A1/es not_active Application Discontinuation
- 1999-04-16 JP JP11109629A patent/JPH11322713A/ja not_active Withdrawn
- 1999-04-16 CA CA002269246A patent/CA2269246C/en not_active Expired - Fee Related
- 1999-04-16 EP EP99302941A patent/EP0952149B1/en not_active Expired - Lifetime
- 1999-04-16 AT AT99302941T patent/ATE268756T1/de not_active IP Right Cessation
- 1999-04-16 HU HU9901220A patent/HUP9901220A3/hu unknown
- 1999-04-16 ES ES99302941T patent/ES2222663T3/es not_active Expired - Lifetime
- 1999-04-16 PE PE1999000314A patent/PE20000432A1/es not_active Application Discontinuation
- 1999-04-16 CZ CZ991370A patent/CZ137099A3/cs unknown
- 1999-04-16 JP JP15240099A patent/JP4435330B2/ja not_active Expired - Fee Related
- 1999-04-16 CZ CZ991369A patent/CZ136999A3/cs unknown
- 1999-04-16 NO NO19991821A patent/NO314400B1/no not_active IP Right Cessation
- 1999-04-16 SG SG9901681A patent/SG81976A1/en unknown
- 1999-04-16 PL PL99332566A patent/PL332566A1/xx not_active Application Discontinuation
- 1999-04-16 NZ NZ507564A patent/NZ507564A/xx unknown
- 1999-04-16 SI SI9930650T patent/SI0950657T1/xx unknown
- 1999-04-16 BR BR9901279-0A patent/BR9901279A/pt not_active IP Right Cessation
- 1999-04-16 TR TR1999/00853A patent/TR199900853A2/xx unknown
- 1999-04-16 ZA ZA9902772A patent/ZA992772B/xx unknown
- 1999-04-16 CA CA002269262A patent/CA2269262A1/en not_active Abandoned
- 1999-04-16 TW TW088106130A patent/TWI238160B/zh not_active IP Right Cessation
- 1999-04-16 PT PT99302967T patent/PT950657E/pt unknown
- 1999-04-16 AU AU23817/99A patent/AU753436B2/en not_active Ceased
- 1999-04-16 DE DE69918590T patent/DE69918590T2/de not_active Expired - Lifetime
- 1999-04-16 ZA ZA9902771A patent/ZA992771B/xx unknown
- 1999-04-16 PL PL99332565A patent/PL332565A1/xx not_active Application Discontinuation
- 1999-04-16 NZ NZ335253A patent/NZ335253A/xx unknown
- 1999-04-16 EP EP99302967A patent/EP0950657B1/en not_active Expired - Lifetime
- 1999-04-16 EA EA199900301A patent/EA002347B1/ru not_active IP Right Cessation
- 1999-04-16 YU YU19199A patent/YU19199A/sh unknown
- 1999-04-16 KR KR1019990013438A patent/KR100586761B1/ko not_active Expired - Fee Related
- 1999-04-16 NO NO19991822A patent/NO312240B1/no not_active IP Right Cessation
- 1999-04-16 DK DK99302967T patent/DK0950657T3/da active
- 1999-04-16 NZ NZ335251A patent/NZ335251A/xx unknown
- 1999-04-16 DE DE69917833T patent/DE69917833T2/de not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000476A1 (es) | Compuestos triciclicos sustituidos | |
| TW265337B (es) | ||
| ES8401027A1 (es) | Procedimiento para la obtencion de acidos 1-carboxi-(alcanoil o aralcanoil)-indolin-2-carboxilicos. | |
| ATE324897T1 (de) | Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern | |
| DE50100893D1 (de) | Verfahren zur Herstellung von 3,4-Alkylendioxythiophen-2,5-dicarbonsäurederivaten | |
| ES2169871T3 (es) | Empleo de poliacidos para el tratamiento de fertilizantes minerales que contienen un inhibidor de nitrificado. | |
| ATE177081T1 (de) | 1h-indol-3-essigsäure-hydrazid als spla2 inhibitoren | |
| PE57399A1 (es) | Sulfamidas utiles como inhibidores de metaloproteasas | |
| EA200100457A1 (ru) | Способ получения циталопрама | |
| DE3770095D1 (de) | Chinazolindione und pyridopyrimidindione. | |
| PT90623A (pt) | Processo para a preparacao de n-heterociclil-4-guanilalquil-benzamidas uteis como inibidores de protease | |
| PT88992A (pt) | Processo para a preparacao de compostos contendo fosforo uteis como inibidores de colagenase | |
| PE20000472A1 (es) | Compuestos triciclicos sustituidos | |
| ATE66240T1 (de) | Phenolische korrosionsinhibitoren fuer anstrichstoffe. | |
| SE8101211L (sv) | Antihypertensiva aminer | |
| ES8705224A1 (es) | Procedimiento para la obtencion de imidazoles sustituidos | |
| ES8703424A1 (es) | Procedimiento para la obtencion de compuestos de amida | |
| ES2038614T3 (es) | 7-(fenilacetamido)-4-alquilcumarina, procedimiento para su preparacion asi como su empleo en procedimiento para la determinacion de la actividad de hidrolasas, especialmente de penicilina-g-acilasa. | |
| PT81530B (pt) | Processo para a resolucao optica de misturas racemicas de acidos alfa-naftil-proplonicos | |
| FR2496638B1 (es) | ||
| ES2096066T3 (es) | Procedimiento de desdoblamiento de hidantoinas quirales. | |
| ATE17946T1 (de) | 3-chlor-3-phenylprop-2-en ylthiophosphorsaeureester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen. | |
| SE7709693L (sv) | Acyloxi-n,n'-diacylmalonamider samt forfarande for framstellning derav | |
| DE59408751D1 (de) | Verfahren zur Herstellung von Fettsäureamiden und ihre Verwendung | |
| ATE25088T1 (de) | Thiolphosphorsaeureester, ihre herstellung und verwendung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |